Inventor
SPITS HERGEN
NL29 patents
⚠️ This page may combine multiple inventors who share the name “SPITS HERGEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SPITS HERGEN
6 patentsUS8562996B2Oct 22, 2013
RSV-specific binding molecules and means for producing them
SPITS HERGEN33 citations95
US9005974B2Apr 14, 2015
Means and methods for influencing the stability of cells
SPITS HERGEN5 citations83
US9127251B2Sep 8, 2015
Means and methods for influencing the stability of antibody producing cells
SPITS HERGEN10 citations79
US8389281B2Mar 5, 2013
Materials and methods relating to the production and maintenance of cell lines
SPITS HERGEN11 citations79
US8318487B2Nov 27, 2012
Materials and methods relating to the production and maintenance of cell lines
SPITS HERGEN11 citations79
US9718874B2Aug 1, 2017
Influenza A virus specific antibodies
SPITS HERGEN2 citations68
AIMM THERAPEUTICS BV
5 patentsUS11136407B2Oct 5, 2021
Therapeutic anti-CD9 antibody
AIMM THERAPEUTICS BV0 citations50
US10344076B2Jul 9, 2019
Means and methods for producing high affinity antibodies
AIMM THERAPEUTICS BV0 citations50
US9969795B2May 15, 2018
Means and methods for producing high affinity antibodies
AIMM THERAPEUTICS BV0 citations49
US10556963B2Feb 11, 2020
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
AIMM THERAPEUTICS BV0 citations45
US10690658B2Jun 23, 2020
Means and methods for determining T cell recognition
AIMM THERAPEUTICS BV0 citations39
SCHERING CORP
4 patentsUS5837232ANov 17, 1998
Use of an interleukin-10 antagonist to treat a B cell mediated autoimmune disorder
SCHERING CORP30 citations92
US5776451AJul 7, 1998
Use of interleukin-10 in adoptive immunotherapy of cancer
SCHERING CORP29 citations92
US5837293ANov 17, 1998
Use of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicity
SCHERING CORP9 citations73
US5833976ANov 10, 1998
Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
SCHERING CORP9 citations72
KLING BIOTHERAPEUTICS B V
4 patentsUS12084681B2Sep 10, 2024
Ex vivo antibody production
KLING BIOTHERAPEUTICS B V0 citations57
US11629200B2Apr 18, 2023
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
KLING BIOTHERAPEUTICS B V0 citations54
US11524989B2Dec 13, 2022
AML antigens and uses thereof
KLING BIOTHERAPEUTICS B V0 citations51
US11999793B2Jun 4, 2024
Therapeutic anti-CD9 antibody
KLING BIOTHERAPEUTICS B V0 citations49
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM
4 patentsUS10774308B2Sep 15, 2020
Means and methods for influencing the stability of cells
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM0 citations51
US10077427B2Sep 18, 2018
Means and methods for influencing the stability of cells
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM0 citations51
US10273454B2Apr 30, 2019
Means and methods for influencing the stability of antibody producing cells
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM0 citations47
US9822339B2Nov 21, 2017
Means and methods for influencing the stability of antibody producing cells
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM0 citations47
MEDIMMUNE LTD
3 patentsUS10059757B2Aug 28, 2018
RSV-specific binding molecules and means for producing them
MEDIMMUNE LTD8 citations83
US9321831B2Apr 26, 2016
RSV-specific binding molecules and means for producing them
MEDIMMUNE LTD8 citations83
US10730931B2Aug 4, 2020
RSV-specific binding molecules and means for producing them
MEDIMMUNE LTD3 citations72